Long-Term Overall Survival and Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer

In this segment, Dr. Graham and Dr. Sokolova transition the discussion from biochemical recurrence to metastatic castration-sensitive prostate cancer (mCSPC), focusing on the impact of mature overall survival data from multiple clinical trials. The conversation highlights how longer follow-up has influenced clinician perspectives on early treatment intensification and long-term disease control. Dr. Graham discusses how improved survival outcomes have shifted expectations toward more proactive management earlier in the disease course, while emphasizing the importance of individualized treatment selection. Both experts note that long-term data provide greater insight into durability of benefit, sequencing considerations, and the balance between maximizing efficacy and managing cumulative toxicity. The discussion reinforces that interpretation of these results requires careful consideration of trial populations and treatment strategies. Overall, this segment underscores how evolving long-term survival evidence is shaping contemporary decision-making in mCSPC and informing discussions around early intervention and sustained disease management.